{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-030275","form_type":"8-K","ticker":"FBRX","cik":"0001419041","company_name":"Forte Biosciences, Inc.","filed_at":"2023-02-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.861590+00:00","generated_at":"2026-06-19T19:54:12.448128+00:00","sec_items":["5.03","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"Forte Biosciences amends bylaws to update stockholder meeting procedures","bullets":["Bylaws revised to require stockholder nominating directors to deliver evidence of Rule 14a-19 compliance at least 5 business days before meeting.","Changes conform to recent amendments to the Delaware General Corporation Law.","Amendments also include ministerial and clarifying revisions to align with current Delaware law."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-030275","json":"https://secwatch.observer/filing/0001193125-23-030275.json","markdown":"https://secwatch.observer/filing/0001193125-23-030275.md","text":"https://secwatch.observer/filing/0001193125-23-030275.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1419041/000119312523030275/0001193125-23-030275-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1419041/000119312523030275/d466499d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T19:54:12.448128+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f81ede67d247e3d677e955a4636cffb297166f1f","claim":"Forte Biosciences, Inc.: Amended and restated bylaws to revise director nomination procedures, stockholder meeting procedures, and make ministerial changes to conform to Delaware law (effective 2023-02-07).","evidence_excerpt":"On February 7, 2023, the Board of Directors (the “Board”) of Forte Biosciences, Inc. (the “Company”), acting upon the recommendation of the Nominating and Corporate Governance Committee of the Board, amended and restated the Company’s amended and restated bylaws, effective immediately.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1419041/000119312523030275/0001193125-23-030275-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2023-02-07"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}